Clinical development of trastuzumab in breast cancer

被引：4
|
作者：
Tokuda Y. [1 ]
Ohta M. [1 ]
Suzuki Y. [1 ]
Kubota M. [1 ]
Tajima T. [1 ]
机构：
[1] Department of Surgery, Tokai University School of Medicine
来源：
Breast Cancer | 2001年 / 8卷 / 2期
关键词：
Breast cancer; HER2/neu; Humanized monoclonal antibody; Trastuzumab;
D O I：
10.1007/BF02967486
中图分类号：
学科分类号：
摘要：
The HER-2/neu protein is thought to be a unique and useful target for antibody therapy of cancers overexpressing the HER-2/neu gene. The recombinant humanized anti-HER-2 monoclonal antibody, trastuzumab (Herceptin ™) is now available for clinical use in the U.S.A. It is also expected to be available in Japan in the near future. In this paper, the details of this novel biologic agent are reviewed in conjunction with a phase I study performed in Japan.
引用
收藏
页码：93 / 97
页数：4
相关论文
共 50 条
  • [41] Trastuzumab Cardiotoxicity in Patients with Breast Cancer
    Freitas, Aguinaldo Figueiredo, Jr.
    Rassi, Salvador
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2014, 102 (02) : 200 - 200
  • [42] Trastuzumab Therapy for Early Breast Cancer
    Charbonneau, Flay
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2006, 59 : 41 - 42
  • [43] Trastuzumab safe in breast cancer progression?
    Reactions Weekly, 2004, 1005 (1) : 4 - 4
  • [44] Trastuzumab Deruxtecan for Breast Cancer REPLY
    Cortes, Javier
    Im, Seock-Ah
    Cathcart, Jillian
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (24): : 2347 - 2347
  • [45] Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation
    Jackisch, Christian
    Scappaticci, Frank A.
    Heinzmann, Dominik
    Bisordi, Fabio
    Schreitmuller, Thomas
    von Minckwitz, Gunter
    Cortes, Javier
    FUTURE ONCOLOGY, 2015, 11 (01) : 61 - 71
  • [46] CARDIOPROTECTION ALLOWS RECHALLENGE WITH TRASTUZUMAB IN BREAST CANCER. A MULTIDISCIPLINARY CLINICAL CASE FROM BREAST UNIT
    Fioretti, A.
    Leopizzi, T.
    Giotta, F.
    Latorre, A.
    Lorusso, V.
    Oliva, S.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0C) : C84 - C84
  • [47] Trastuzumab/trastuzumab emtansineDevelopment of resistance in metastatic breast cancer: case report
    Reactions Weekly, 2017, 1646 (1) : 318 - 318
  • [48] The development and clinical use of trastuzumab (Herceptin)
    Harries, M
    Smith, I
    ENDOCRINE-RELATED CANCER, 2002, 9 (02) : 75 - 85
  • [49] Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
    Jeyakumar, Alwin
    Younis, Tallal
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [50] Cardiac monitoring and toxicity with adjuvant trastuzumab in breast cancer: Data from clinical practice
    Dienstmann, R.
    Viola, S.
    Chueke, M.
    Takemoto, M.
    Teich, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345